Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
OKUR 
OnKure Therapeutics, Inc. (OKUR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: OKUR (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $30
1 Year Target Price $30
| 5 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -26.05% | Avg. Invested days 21 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 38.97M USD | Price to earnings Ratio - | 1Y Target Price 30 |
Price to earnings Ratio - | 1Y Target Price 30 | ||
Volume (30-day avg) 6 | Beta - | 52 Weeks Range 1.70 - 19.40 | Updated Date 10/17/2025 |
52 Weeks Range 1.70 - 19.40 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.46 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -70.95% | Return on Equity (TTM) -142.9% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -44667110 | Price to Sales(TTM) - |
Enterprise Value -44667110 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.57 | Shares Outstanding 12843434 | Shares Floating 5798265 |
Shares Outstanding 12843434 | Shares Floating 5798265 | ||
Percent Insiders 1.73 | Percent Institutions 87.13 |
Upturn AI SWOT
OnKure Therapeutics, Inc.
Company Overview
History and Background
OnKure Therapeutics is a biopharmaceutical company focused on developing innovative medicines targeting critical pathways in cancer and other diseases. Founded relatively recently, it is dedicated to translating groundbreaking science into transformative therapies. Specific founding year and detailed milestones are unavailable in the public domain.
Core Business Areas
- Drug Development: Focuses on the discovery and development of small molecule therapeutics for oncology and other diseases.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
- Research and Innovation: Invests in research to identify new drug targets and develop novel therapies.
Leadership and Structure
Information on the specific leadership team and organizational structure is limited in publicly available sources. Generally, such companies have a CEO, CSO, and other key executives overseeing research, development, and business operations.
Top Products and Market Share
Key Offerings
- OKI-179: A PI3Ku03b1 inhibitor under development for advanced solid tumors. Specific market share data and revenue are unavailable as it's still in clinical trials. Competitors include companies developing other PI3K inhibitors such as Novartis (BYI.SW) and Bayer (BAYN.DE).
- OKI-219: An oral HDAC inhibitor under development for hematologic malignancies and solid tumors. Specific market share data and revenue are unavailable as it's still in clinical trials. Competitors include companies developing other HDAC inhibitors such as Celgene (acquired by Bristol Myers Squibb - BMY) and Merck (MRK).
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and research-intensive, focused on developing new treatments for diseases. It's characterized by high regulatory hurdles and significant investment in research and development.
Positioning
OnKure is positioned as a clinical-stage biopharmaceutical company aiming to address unmet medical needs in oncology. Its competitive advantage lies in its focus on specific targets and its proprietary drug development platform.
Total Addressable Market (TAM)
The total addressable market for oncology therapeutics is substantial, estimated at hundreds of billions of dollars annually. OnKure is positioned to capture a portion of this TAM by successfully developing and commercializing its drug candidates.
Upturn SWOT Analysis
Strengths
- Novel drug candidates
- Experienced management team
- Proprietary drug development platform
- Focus on unmet medical needs
Weaknesses
- Limited financial resources
- Early-stage development pipeline
- High clinical trial risk
- Dependence on external funding
Opportunities
- Successful clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Acquisition by a larger company
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Changes in healthcare reimbursement policies
Competitors and Market Share
Key Competitors
- BMY
- MRK
- BAYN.DE
- NVS
Competitive Landscape
OnKure faces intense competition from larger, established pharmaceutical companies with greater resources and more advanced pipelines. Its success depends on the clinical success of its novel drug candidates and its ability to secure funding and partnerships.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data not available due to lack of public financial data.
Future Projections: Future projections are dependent on clinical trial outcomes and potential partnerships. Analyst estimates are not available due to its private status.
Recent Initiatives: Recent initiatives focus on advancing its clinical programs and securing funding for further development.
Summary
OnKure Therapeutics is a promising, privately held biopharmaceutical company developing novel cancer therapies. Its success hinges on positive clinical trial outcomes for its lead compounds. The company faces the challenges of a competitive landscape and the need for substantial funding to advance its pipeline. Successful partnerships and potential acquisition by a larger pharmaceutical company could accelerate its growth trajectory.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- ClinicalTrials.gov
- SEC Filings of Competitors
- Industry Reports
Disclaimers:
The information provided is based on publicly available data and is for informational purposes only. It should not be construed as investment advice. Market share data are estimates and may not be precise. As OnKure is private, financial data and detailed operational insights are limited.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About OnKure Therapeutics, Inc.
Exchange NASDAQ | Headquaters Boulder, CO, United States | ||
IPO Launch date 2024-10-07 | President, CEO & Director Dr. Nicholas A. Saccomano Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 46 | Website https://onkuretherapeutics.com |
Full time employees 46 | Website https://onkuretherapeutics.com | ||
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3 kinase alpha harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company is headquartered in Boulder, Colorado.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.